Search Results

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

February 2022 "InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating to unlock orphan targets leveraging InterAx AI driven discovery platform. first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic need. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical companies #ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

Every biotech founder fears the day the cash runs out. You track the burn rate. Here are the three most common sources of internal drift in early biotech teams: 1️⃣ Scientific versus Most biotech founders don’t suffer from having the wrong people. A soft skill. ✅ But in biotech, alignment is a multiplier. It’s how biotech companies move from drift to direction.

and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr. GPCR Ecosystem Enjoying the Dr.

He is Chief Scientific Officer and co-founder of InterAx Biotech, where he specializes in the development Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr. They wrapped up the conversation by discussing job opportunities at Interax Biotech and their anticipation Aurelien Rizk, a co-founder and CEO of Interax Biotech, shared about the company's development of a discovery The discussion concluded with a brief overview of job opportunities at Interax Biotech, with Aurelien

GPCR — Scaling Biotech Beyond the Bench Turning scientific excellence into scalable organizations. Our work helps biotech startups, research organizations, and CROs design operating systems that enable Bu Attila Foris 5 days ago The One Reason Why Biotech Startups Fail More Often Than They Should Biotech When complexity grows faster than strategy, biotech companies drift. Biotech fundraising has undergone a subtle yet significant shift.